Skip to content

Ketamine-Assisted Group Therapy for Work-Related Stress in First Responders and Frontline Health Care Workers

Luke Flynn, Mary Rondeau, Martin Krsak, Scott Shannon

Psychedelic Medicine April 21, 2025 DOI: 10.1089/psymed.2024.0050 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pre-post intervention study Peer reviewed
Sample size 16
Population First responders and frontline health care workers with work-related stress
Intervention Ketamine-assisted psychotherapy
Duration 6-week intervention
Topics Ketamine Esketamine
Keywords Health care Nursing Clinical psychology
Citations 1
Key points Symptoms of trauma, anxiety, and depression were significantly reduced after a 6-week group ketamine-assisted psychotherapy program.

Abstract

Introduction: Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder. Ketamine-assisted psychotherapy (KAP) is part of an emerging model of psychedelic medicine that employs psychoactive agents to support the psychotherapeutic process. Frontline health care workers and first responders encountered excessive levels of job stress, especially during the COVID-19 pandemic. This article reports on a 6-week community-based group-KAP program to address symptoms of trauma, anxiety, and depression in a sample of first responders and frontline health care workers.

Methods: Recruitment was self-directed based on a sense of work-related stress. All participants completed a 6-week ketamine-assisted psychotherapy group intervention with three to six participants per group. The group characteristics and repeated measures comparisons were analyzed via descriptive statistics, pre- and post-intervention measure comparisons and regression modeling.

Results: Sixteen patients received KAP in small groups with “pre” and “post” treatment evaluation of anxiety (Generalized Anxiety Disorder–7), depression (Patient Health Questionnaire–9), and trauma (Posttraumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition). Symptoms of trauma, anxiety, and depression were significantly reduced ( p < 0.002) from “pre” to “post” test.

Conclusion: These results suggest that the community-based group-KAP program described here may be a useful treatment for work-related stress, though further formal evaluation is required. Future directions, limitations, and interpretations are discussed.

Comparable studies

Other non-randomized and open-label trials on ketamine, most cited first.

Study Year Design Participants
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Intravenous arketamine for treatment-resistant depression: open-label pilot study Humans with treatment-resistant depression 2020 Open-label pilot trial n = 7
A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide. Hospitalized patients with Major Depressive Disorder and acute suicidal ideation and... 2024 Open label study n = 17
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Alcoholic patients 1997 Controlled clinical trial n = 211
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression Participants with DSM-IV-defined major depressive disorder and treatment-resistant... 2014 Pooled analysis of three clinical trials n = 97

Citations in the library

Explore topics